Nurulimab
Based on 1 Customer Validation
Nurulimab is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) human monoclonal antibody. Nurulimab binds to CTLA-4 and blocks its interaction with ligands, stimulating T-cell proliferation, cytokine production, and inducing an antitumor immune response. Nurulimab can be used for the research of unresectable or metastatic melanoma and advanced cutaneous melanoma.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 95.00%
- CAS No.: 2168561-20-2
- Masse moléculaire:143.78 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Human IgG1 kappa
Human
CTLA4
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Flow Cytometry analysis of Raji cells labelling CTLA4 (red) with Nurulimab (anti-CTLA4) (HY-P99760). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.
Chemical Information
-
CAS No. 2168561-20-2
-
Appearance Liquid
-
Masse moléculaire 143.78 kDa
-
Color Colorless to light yellow
-
SMILES
[Nurulimab]
-
Synonyms
BCD-145
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)